Literature DB >> 17552392

Epiretinal deposit of triamcinolone acetonide at the posterior pole after intravitreal injection.

Gesine B Jaissle1, Peter Szurman, Michael Völker, Karl Ulrich Bartz-Schmidt.   

Abstract

The authors investigated possible toxic side effects of epiretinal triamcinolone acetonide deposits at the posterior pole after an intravitreal injection in both a vitrectomized and a non-vitrectomized eye. The vitrectomized eye developed massive epiretinal triamcinolone acetonide deposits at the posterior pole that were less pronounced in the non-vitrectomized eye. After resolution of the deposits, no morphologic signs of retinal toxicity were apparent. Mild scattered visual field defects did not correlate with the localization of the triamcinolone acetonide deposits. However, because recent in vitro studies indicate potential cytotoxicity, patients should be instructed to keep their heads in an upright position after intravitreal triamcinolone acetonide injection to avoid deposits at the posterior pole.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17552392     DOI: 10.3928/15428877-20070501-10

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  3 in total

1.  [Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists for intravitreal treatment of macular edema in uveitis: Date: 02/07/2014].

Authors:  A Heiligenhaus; B Bertram; C Heinz; L Krause; U Pleyer; J Roider; S Sauer; S Thurau
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

2.  [Optic atrophy subsequent to epiretinal triamcinolone deposits in an eye following inner limiting membrane peeling].

Authors:  G B Jaissle; K U Bartz-Schmidt; P Szurman
Journal:  Ophthalmologe       Date:  2008-06       Impact factor: 1.059

3.  Gravity influences bevacizumab distribution in an undisturbed balanced salt solution in vitro.

Authors:  Rae Young Kim; Soonil Kwon; Ho Ra
Journal:  PLoS One       Date:  2019-10-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.